Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ Subcutaneous Maintenance Dose for Early Alzheimer's Treatment

journey, the LEQEMBI Companion app was developed with Medisafe, a digital patient engagement and medication management platform. From educational information about the injection process to a tool for tracking where and when injections occur, the...

CareDx Announces IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE®

of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. For more information, please visit www.caredx.com.

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Are Now Available at Over 50 iCRYO Clinics and More Than 900 Clinics Nationwide

effective and efficient. With Niagen, we are equipping our franchisees and serving our guests with the very best.” Outperforming NAD+ IV in a pilot clinical study, Niagen IV offers superior tolerability, a 75% shorter infusion time (30-45 minute...

Novartis Receives FDA Approval for Rhapsido® (remibrutinib), the First Oral, Targeted BTKi Treatment for Chronic Spontaneous Urticaria (CSU

CSU across many countries, including in the European Union, Japan, and China, with priority review granted in China. Transforming care in Immunology "This approval of Rhapsido as the first and only BTK inhibitor in CSU is an important milestone in...

CollPlant Biotechnologies Announces Positive Non-Clinical Study Results for Its Photocurable Regenerative Dermal and Soft Tissue Filler

integrating contouring precision, structural support, and tissue regeneration into a single treatment. CollPlant's formulation combines hyaluronic acid with a modified form of rhCollagen to deliver both immediate and long-lasting benefits....

Corstasis Therapeutics and U.S. Heart and Vascular® will collaborate to improve heart failure care with ENBUMYST™ (Bumetanide Nasal Spray

heart failure, and hepatic and renal disease, including nephrotic syndrome in adults. INDICATION AND IMPORTANT SAFETY INFORMATION FOR ENBUMYST™ (BUMETANIDE NASAL SPRAY). INDICATION: ENBUMYST is indicated for the treatment of edema associated with...

Leqembi® has received approval for intravenous maintenance treatment in China

or the regimen of 10 mg/kg once every two weeks may be continued. AD is a progressive, relentless disease characterized by formation of protein deposits known as plaques made of amyloid-beta aggregates and neurofibrillary tangles made of tau...

At the Heart Failure Society of America, Bayer will showcase new data for KERENDIA® (finerenone)

with heart failure with left ventricular ejection fraction (HF LVEF) ≥40% (10mg, 20mg, 40mg tablets) IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS: Hypersensitivity to any component of this product Concomitant use with strong CYP3A4 inhibitors...

Upsher-Smith Enhances Generics Portfolio by Introducing Difluprednate Ophthalmic Emulsion

improve patients' quality of life. By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. For more information, please visit www.bora-corp.com.

European Commission Approves Alteogen’s Aflibercept Biosimilar, EYLUXVI® (ALT-L9)

long-acting therapeutic proteins and next-generation ADCs, developed by its proprietary NexP™-fusion and NexMab™ platform technology, respectively. It also developed a proprietary recombinant human hyaluronidase enzyme utilizing Hybrozyme™...

Sanguine Expands Oncology Biospecimen Portfolio via Strategic Clinic Partnerships

development, and potential therapeutic targets prior to intervention. Sanguine leverages its integrated technology platform to streamline data and donor engagement. By securely importing electronic medical records (EMRs) directly from clinic...

LOTUS study data on DAYBUE® (trofinetide) for Rett Syndrome's long-term efficacy and tolerability is published in Developmental Medicine and Child Neurology

has been shown to increase branching of dendrites and synaptic plasticity signals.10 Indication and Important Safety Information for DAYBUE® (trofinetide) Indication DAYBUE is indicated for the treatment of Rett syndrome in adults and pediatric...

Optune Lua® from Novocure has received approval in Japan for treating unresectable advanced/recurrent Non-Small Cell Lung Cancer (NSCLC)

balanced between cohorts: median age was 65 years (range, 22-86); 66% male, 34% female; 96% of patients had an ECOG performance status of 0-1. PD-L1 expression data were collected from 83% of patients (69 of 83 patients) enrolled at U.S. sites and...

At the American Thyroid Association meeting, FORE Biotherapeutics presented Phase 1/2a data for Plixorafenib, demonstrating a prolonged duration of effect in BRAF-altered thyroid cancers

FORTE basket study, which includes BRAF V600 altered thyroid cancers, as we aim to generate further data to inform treatment and help patients with BRAF driven tumors.” The results presented at ATA 2025 are from 21 patients with thyroid cancer, 16...

At the PHPN 2025 Symposium, Corsair Pharma will present new data on its proprietary transdermal system for Treprostinil prodrug

aggregation and smooth muscle proliferation. Treprostinil is currently marketed by United Therapeutics in different dosage forms to alleviate the symptoms, maintain or improve functional class, delay disease progression, and improve quality of life...

Medicines Discovery Catapult and Crown Bioscience form a global alliance for radiopharmaceutical innovation

Medicines Discovery Catapult (MDC) and Crown Bioscience have formed a strategic global collaboration to deliver an integrated translational biology platform for innovators developing radiopharmaceuticals. Radiopharmaceuticals are a growing class...

Marius Pharmaceuticals and Hims & Hers™ collaborate to expand access to KYZATREX® (testosterone undecanoate) CIII capsules, the first FDA-approved oral testosterone therapy available on the Hims & Hers platform

Marius Pharmaceuticals, Inc. announced a collaboration with Hims & Hers™, one of the largest digital health platforms for men, to make KYZATREX®, an FDA-approved oral testosterone replacement therapy for adult men with low or no testosterone...

Waldencast announces the FDA approval of Obagi® saypha® MagIQ™ injectable hyaluronic acid gel under the Obagi Medical brand

Waldencast plc a global multi-brand beauty and wellness platform, announced that the U.S. Food and Drug Administration (“FDA”) has approved Obagi® saypha® MagIQ™ injectable hyaluronic acid (“HA”) gel, the first product in the Obagi® saypha®...

At World Sleep 2025, Avadel Pharmaceuticals will present new data on LUMRYZ™ (sodium oxybate) for extended-release oral suspension

Avadel Pharmaceuticals plc a biopharmaceutical company focused on transforming medicines to transform lives, today announced that new data supporting the use of LUMRYZ as a narcolepsy treatment will be presented in one oral presentation and 16...

Nuvation Bio unveils new data on IBTROZI™ (taletrectinib) in advanced ROS1-positive non-small cell lung cancer

the recent approval of IBTROZI in the U.S., which has added an important new option for a range of patients with this form of lung cancer, regardless of prior exposure to tyrosine kinase inhibitor therapy.” “Disease progression remains one of the...